Long-term use of AstraZeneca’s Brilinta in patients with a history of heart attack reduces the risk of cardiovascular death by 29 percent, a new sub analysis of data from the Phase III PEGASUS-TIMI 54 trial has found.
News
Novartis breast cancer drug Kisqali wins EU approval
Novartis has announced the launch of its new breast cancer drug Kisqali in the UK today following a green light from European regulators.
NHS England moves to pull in overseas doctors
NHS England is setting up a GP International Recruitment Office to help deliver its target of recruiting 2,000 overseas doctors to join the GP workforce in England over the next three years.
NICE rejects thyroid cancer drugs
It is looking likely that patients in England will loose NHS access to Ipsen’s Cometriq and Sanofi Genzyme’s Caprelsa via the Cancer Drugs Fund, after cost-regulators turned down funding for their use.
CR UK trials early-stage Lilly drug
Cancer Research UK has launched a new multi-site trial of an early-stage experimental therapy owned by Eli Lilly assessing its potential in a range of advanced cancers.
MMIP call for support to boost medicines manufacturing in the UK
The Medicines Manufacturing Industry Partnership (MMIP) is requesting government funds to help set up four new Centres of Excellence for medicines manufacturing across the UK, in line with wider plans to build on the exporting strengths of the country’s biopharma sector.
Orchard’s ‘bubble baby’ therapy awarded PIM status
UK regulators have awarded Orchard Therapeutics’ experimental ‘bubble baby’ disease therapy OTL-101 Promising Innovative Medicine status, pushing the drug closer to being accepted onto the Early Access to Medicines Scheme.
New flu vaccine approved for UK use
The Medicines and Healthcare products Regulatory Agency has cleared the adjuvanted trivalent influenza vaccine Fluad for use in people aged 65 years or older.
Novartis launches MS smartphone trial
Novartis has kicked off a mobile research study for people with multiple sclerosis (MS) that collects data remotely via their smartphone.
Samsung Bioepis ventures into novel R&D with Takeda deal
Samsung Bioepis is joining forces with Takeda Pharmaceutical to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas, taking its first step towards developing new pharmaceuticals.
J&J ordered to pay $417m fine in cancer talc case
Johnson & Johnson has been ordered by a jury in California to pay $417 million to a woman who claims to have developed ovarian cancer from regular use of its talc-based products.
PharmaTimes Communications Team of the Year fully booked ahead of the closing date
Due to unprecedented demand, the prestigious PharmaTimes Communications Team of the Year 2017 competition is now fully booked.
Novartis takes aim at drug-resistant Malaria
The company and Medicines for Malaria Venture launch trial for next-gen antimalarial compound
Pfizer berates NICE over ALL drug decision
Firm believes NICE inappropriately assessed the value of the drug
AstraZeneca announces new mRNA collaboration
Company will partner with Ethris in respiartory disease
